explore -WSS

explore

author：leisure time 2025-09-28 02:31:19 - browse：5

portrait of Jennifer Adair -- coverage from STAT — Jennifer Adair develops scalable, low cost gene therapies at the Fred Hutchinson Cancer Center and helped found the Global Gene Therapy Initiative. Fred Hutch News Service

BALTIMORE — Gene and cell therapies have transformed a handful of devastating disorders in the U.S. and Europe, with more treatments on the way. But those technologies have largely failed to reach most of the world.

These lags are ubiquitous in the current drug development system, where new therapies are approved in wealthy countries and then slowly leak out to low- and middle-income countries, many years later. In the case of gene therapy, that means countries most affected by a disease such as sickle cell may wait decades to access a curative therapy.

For the last few years, a handful of researchers in the U.S. and around the world have tried to find ways of ensuring global access to these technologies. In 2020, they formed the Global Gene Therapy Initiative, with an initial goal of setting up a gene therapy clinical trial for a hemoglobinopathy — such as a disease like sickle cell or beta thalassemia — or HIV in two different low- and middle-income countries by 2024.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Changes to biosimilar regulatory framework must prioritize patients

hotspot

WSS

Senators: Long

EpiPen alternative approval delay highlights citizen petition issue

Senate HELP committee spars over health care workforce policies

Biotech lab space demand falls sharply

Ukraine and a new approach to mental health in war

Senators: Long

leisure time

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Drug repurposing or repositioning? The language matters

Hearing on Medicare drug price negotiation gets unusually heated

The cancer drug shortage isn’t new — and neither are the solutions

CDC advisers recommend seasonal use of Pfizer RSV shot

Medicare proposal to cover medical devices draws a mixed reaction

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Dobbs anniversary: the lost opportunity of abortion as health care

Biotech stock slump in 2023: awaiting the turnaround

Jerome Adams on the need for new antivirals for Covid

Senate HELP committee spars over health care workforce policies

focus

Lasker Awards 2023: Winners in biomedical research

Why are Kaiser Permanente staff considering a strike?

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Hearing on Medicare drug price negotiation gets unusually heated

Senators: Long

Thermo Fisher plant for manufacturing gene therapies to expand

hotspot

hotspot

Wikipedia

Wikipedia